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In the originally published version of this article, a statement in the discussion was not updated to reflect the data finally presented in
Figure 1. The original publication contained the following statement: (3) ‘‘Differing V2-apex iP reactivity. The most effective immuno-
gens, C108 and CRF250, bind all of the PG9, CH01, and CAP256 prototype iPs, while WITO andMGRM8 are neutralized by only two
of these antibodies. Further, WITO and MGRM8 SOSIPs showed the poorest binding to iP/UCA antibodies by BLI, suggesting there
are potentially fewer ways for them to trigger naive BCRs.’’ This statement has now been replaced by the following revision:
(3) ‘‘Differing V2-apex iP reactivity. One of the more effective immunogens, CRF250, binds all of the PG9, CH01, and CAP256
precursor antibodies, suggesting there are potentially multiple ways for this trimer specifically to engage V2-apex-directed naive
BCRs and giving it a potential advantage with regard to nAb elicitation.’’
The authors apologize for this error.Cell Reports 22, 1103, January 23, 2018 ª 2017 The Author(s). 1103
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
